Navigation Links
Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical
Date:4/1/2009

First and Only Once-weekly, Self-administered Alternative to Injections for Treatment of Vitamin B12 Deficiency

WOODCLIFF LAKE, N.J., April 1 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced it has acquired the worldwide rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray from QOL Medical LLC. Nascobal Nasal Spray is an FDA approved prescription vitamin B12 supplement indicated to treat vitamin B12 deficiency. It is the first and only once-weekly, self-administered alternative to B12 injections.

Under the terms of the all cash transaction, Strativa Pharmaceuticals will pay QOL Medical $54.5 million for the worldwide rights to Nascobal Nasal Spray. Revenues of Nascobal exceeded $8.0 million in 2008. Nascobal Nasal Spray will be manufactured by Par, which also acquired the MDRNA (formerly Nastech) facility where the product is manufactured.

"The acquisition of Nascobal Nasal Spray represents an important milestone in the execution of our corporate strategy to accelerate the growth of Strativa," said Patrick G. LePore, Chairman, Chief Executive Officer and President of Par. "The addition of Nascobal to our current portfolio, coupled with our promising product pipeline, well positions Strativa within the U.S. specialty pharmaceutical industry."

Millions of Americans are treated for vitamin B12 deficiency. The leading causes of vitamin B12 deficiency include pernicious anemia, a strict vegetarian diet, malabsorption of vitamin B12 resulting from conditions such as HIV infection, AIDS, Crohn's disease, multiple sclerosis and partial or total gastrectomy, among others. In 2008, more than 45 million vitamin B12 injections were prescribed to patients in the Uni
'/>"/>

SOURCE Par Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
2. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
3. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
4. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
5. Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
7. Meeting to examine FDA requirements for manufacturing PET radiopharmaceuticals
8. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
9. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
10. Anadys Pharmaceuticals to Present at the Citi Biotech Day
11. Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... show signs of chronic inflammation in non-cancerous prostate tissue ... prostate cancer than those with no inflammation, according to ... the Johns Hopkins Kimmel Cancer Center. , The link ... men with so-called high-grade prostate cancer those with ... the presence of the most aggressive and rapidly growing ...
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... in lasting psychological scars. This has been proved by ... ,This study was conducted by researchers from Columbia ... of Vietnam War veterans were affected by post-traumatic stress ... higher and lower figures were reported by the contradictory ...
... lay siege on the victim's disposition and way of life, ... coolness can act as an effective pain// reliever. Scientists from ... enable feelings of coolness, and bring immense relief to chronic ... improved treatment measures for people suffering long-term pain, as compared ...
... tests and the presence of various microorganisms has forced the ... ,After a media investigation, Mayor Gerald Tremblay requested mayors ... city's 73 outdoor pools. ,"Public health is important ... conference. "We have to make sure that the safety our ...
... said that Canadian parents appear to have a very rosy ... general they rated Canadian children a C when it came ... commissioned by the CMA. ,It was revealed that ... 9% of Canadian parents considered their own children to be ...
... minors has been supported by President George W. Bush ... the "morning-after"// pill. ,Bush’s statement on ... vote on his nominee Andrew von Eschenbach to head ... ,Von Eschenbach, as acting FDA commissioner has supported nonprescription ...
... blood clots are high during air travel, and not with other ... suggesting// that blood clots can from during any form of travel ... ,The study has revealed that traveling for more than four hours ... clot formation. This was substantiated when the research team analyzed 2000 ...
Cached Medicine News:Health News:Two-thirds of outdoor pools in Montreal are closed 2Health News:Bush Supports Restriction to ‘Morning–After’ P 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... and NEW YORK, Sept. 6, 2011 Galenea ... collaboration to identify synaptic dysfunction linked to Huntington,s ... discovery platform.  Mounting evidence indicates that mutant huntingtin ... synaptic function, contributing to the behavioral, cognitive, and ...
... Sept. 6, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: ... leading domestic developer, manufacturer and marketer of orthopedic implants ... at the Company,s 2011 annual general meeting held in ... Specifically, the shareholders passed resolutions approving: , Re-election ...
Cached Medicine Technology:Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 2Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 3Galenea and CHDI Foundation Announce Collaboration to Identify Key Synaptic Dysfunction in Huntington's Disease 4China Kanghui Holdings Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting 2
... 1 enables hospitals to ... monitors to a single ... temperature monitoring disposale probes ... superior in their manufacture ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
... Excilite- is a portable, compact, lightweight system ... of emitting the same intensity (50 mW/cm) ... a smaller treatment area (30 cm). Excilite- ... to satisfy the most demanding professional users. ...
... advanced system for laser therapy available today. The ... fiber handpiece that allows to perform linear scanning ... 20% of the energy reflected by the skin. ... special gel which optimizes the optical coupling between ...
Medicine Products: